Source | Mean disease duration, years | Inadequate response to (notes) | Active treatment group | Control group | Duration of control, weeks | ||||
Active | N¶ | Mean exposure¶ years | Control | N¶ | Mean exposure¶ years | ||||
Furst et al30 | 10.4 | Standard RA therapy | ADA 40 mg eow + DMARD | 318 | 0.48 | DMARD | 318 | 0.48 | 24 |
van de Putte et al27 | 10.0 | ⩾1 DMARD | ADA 20 mg qw | 72 | 0.22 | Placebo | 70 | 0.17 | 12 |
ADA 40 mg qw | 70 | 0.23 | |||||||
ADA 80 mg qw | 72 | 0.22 | |||||||
Weinblatt et al31 | 12.3 | ⩾1 and ⩽4 DMARD | ADA 20 mg eow + MTX | 69 | 0.39 | MTX | 62 | 0.34 | 24 |
besides MTX | ADA 40 mg eow + MTX | 67 | 0.42 | ||||||
ADA 80 mg eow + MTX | 73 | 0.42 | |||||||
Keystone et al32 | 11.0 | 12.5 mg/week MTX | ADA 20 mg qw + MTX | 212 | 0.90 | MTX | 200 | 0.85 | 54 |
ADA 40 mg eow + MTX | 207 | 0.88 | |||||||
van de Putte et al33 | 11.0 | ⩾1 DMARD | ADA 20 mg qw | 112 | 0.43 | Placebo | 110 | 0.36 | 26 |
ADA 20 mg eow | 106 | 0.42 | |||||||
ADA 40 mg qw | 103 | 0.47 | |||||||
ADA 40 mg eow | 113 | 0.42 | |||||||
Breedveld et al34 | 0.7 | MTX naive | ADA 40 mg eow + MTX | 268 | 1.80 | MTX | 257 | 1.67 | 104 |
ADA 40 mg eow | 274 | 1.59 | |||||||
Moreland et al26 | 12.0 | ⩾1 and ⩽4 DMARD | ETA 10 mg bw | 76 | 0.42 | Placebo | 80 | 0.33 | 24 |
ETA 25 mg bw | 78 | 0.44 | |||||||
Weinblatt et al27 Kremer et al35 | 13.0 | 15–25 mg/week MTX | ETA 25 mg bw + MTX | 59 | 0.45 (3.78†) | MTX | 30 | 0.40 | 24 |
Bathon et al37 | 11.7 | MTX naive | ETA 10 mg bw | 208 | 1.61 | MTX | 217 | 1.58 | 104 |
Genovese et al36 | ETA 25 mg bw | 207 | 1.72 | ||||||
Keystone et al38 | 11.0 | 12.5–25 mg/week | ETA 50 mg qw | 214 | 0.29 | Placebo | 53 | 0.15 | 8 |
MTX | ETA 25 mg bw | 153 | 0.15 (0.19†) | ||||||
Klareskog et al23 van | 6.6 | ⩽1 DMARD excluding | ETA 25 mg bw | 223 | 1.55 | MTX | 228 | 1.44 | 104 |
der Heidje et al39 | MTX | ETA 25 mg bw + MTX | 231 | 1.68 | |||||
Combe et al40 | 6.6 | 2–4 gm/day SSZ | ETA 25 mg bw | 103 | 0.50 | SSZ | 50 | 0.42 | 24 |
ETA 25 mg bw + SSZ | 101 | 0.50 | |||||||
Weisman et al29 | 9.8 | NA Co-morbidities | ETA 25 mg bw | 266 | 0.29 | Placebo | 269 | 0.26 | 16 |
Maini et al25 | 10.0 | 7.5–15 mg/week MTX | IFX 1 mg/kg q4w | 15 | 0.18 | MTX | 14 | 0.21 | 26 |
IFX 1 mg/kg q4w + MTX | 14 | 0.22 | |||||||
IFX 3 mg/kg q4w* | 14 | 0.26 | |||||||
IFX 3 mg/kg q4w + MTX* | 15 | 0.23 | |||||||
IFX 10 mg/kg q4w | 15 | 0.27 | |||||||
IFX 10 mg/kg q4w + MTX | 14 | 0.26 | |||||||
Maini et al25 Lipsky et al24 | 10.6 | ⩾12.5 mg/week MTX | IFX 3 mg/kg q8w + MTX | 88§ | 1.44 | MTX | 86 | 0.97 | 102 |
Maini et al42 | IFX 3 mg/kg q4w + MTX | 86 | 1.51 | ||||||
IFX 10 mg/kg q8w + MTX | 87 | 1.63 | |||||||
IFX 10 mg/kg q8w + MTX | 81 | 1.53 | |||||||
St Clair et al43 | 0.9 | MTX naive | IFX 3 mg/kg q8w + MTX | 372 | 0.94 | MTX | 291 | 0.96 | 54 |
IFX 6 mg/kg q8w + MTX | 377 | 0.93 | |||||||
Abe et al44 | 7.9 | MTX | IFX 3 mg/kg q8w + MTX | 49 | 0.24 | MTX | 47 | 0.26 | 14 |
IFX 10 mg/kg q8w + MTX | 51 | 0.27 | |||||||
Westhovens et al45 | 7.5 | MTX Co-morbidities | IFX 3–9 mg/kg q8w + MTX | 360 | 0.41 (0.54)† | MTX | 363 | 0.41 | 22 |
IFX 3 mg/kg q8w + MTX | 338 | 0.43† | |||||||
IFX 10 mg/kg q8w + MTX | 361 | 0.40 (0.53)† |
ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; IFX, infliximab; MTX, methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; bw, twice per week; eow, every other week; qw, every week. *Classified as recommended dosing. †Exposure after controlled portions of trial. ‡Year 1 exposure. §Two subjects were excluded as they erroneously received one dose. ¶Safety population.